医学
多发性骨髓瘤
自体干细胞移植
内科学
回顾性队列研究
干细胞
移植
细胞遗传学
肿瘤科
病理
生物
遗传学
染色体
基因
作者
Ana Villalba,Ana Pilar González,Javier Arzuaga‐Méndez,Noemí Puig,Mario Arnao,José-María Arguiñano,María Jimenez,Marta Canet,Ana Isabel Teruel,María Sola,Francisco Javier Díaz,Cristina Encinas,Antonio García,Laura Rosiñol,Alexia Suárez,Marta Sonia González,Isabel Izquierdo,Miguel‐Teodoro Hernández,María Stefania Infante,María‐José Sánchez
标识
DOI:10.1080/10428194.2022.2123229
摘要
Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having ≥1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10–82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.
科研通智能强力驱动
Strongly Powered by AbleSci AI